Andrew Benjamin Nixon, PhD

Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • M.B.A., Duke University, 2007
  • Ph.D., Wake Forest University, 1997

Grants

Publications

Innocenti, F., C. Jiang, A. B. Sibley, S. Denning, A. S. Etheridge, D. Watson, D. Niedzwiecki, et al. “A genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients.” In Ann Oncol, 29 Suppl 8:viii661–62, 2018. https://doi.org/10.1093/annonc/mdy303.038.

PMID
32137805
Full Text

Das, R. K., L. Furchtgott, F. -. S. Ou, D. Swanson, B. Hayete, B. Harms, D. Cunha, et al. “Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC).” In Ann Oncol, 29 Suppl 8:viii152, 2018. https://doi.org/10.1093/annonc/mdy281.006.

PMID
32136255
Full Text

Secord, A Alvarez, M. McCollum, B. Davidson, G. Broadwater, R. Squatrito, L. Havrilesky, A. Gabel, A. Nixon, and L. Duska. “PHASE II TRIAL OF NINTEDANIB IN PATIENTS WITH BEVACIZUMAB-RESISTANT RECURRENT EPITHELIAL OVARIAN, TUBAL, AND PERITONEAL CANCER.” In International Journal of Gynecological Cancer, 28:457–457. BMJ PUBLISHING GROUP, 2018.

Scholars@Duke

Vlahovic, Gordana, Kellen L. Meadows, Ace J. Hatch, Jingquan Jia, Andrew B. Nixon, Hope E. Uronis, Michael A. Morse, et al. “A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.” Oncologist 23, no. 7 (July 2018): 782–90. https://doi.org/10.1634/theoncologist.2016-0377.

PMID
29572245
Full Text

Buechel, Megan, Danielle Enserro, Robert Allen Burger, Mark F. Brady, Katrina Wade, Angeles Alvarez Secord, Andrew B. Nixon, et al. “Correlation of imaging and plasma-based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC): A GOG 218 ancillary data analysis.” In Journal of Clinical Oncology, 36:5507–5507. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5507.

Full Text

Jia, Jingquan, Donna Niedzwiecki, Hope Elizabeth Uronis, Michael Morse, Yousuf Zafar, Shiaowen David Hsu, Emily Bolch, et al. “A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood.” In Journal of Clinical Oncology, 36:3555–3555. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.3555.

Full Text

Kim, Richard D., Andrew Stewart Poklepovic, Andrew B. Nixon, Dae Won Kim, Heloisa P. Soares, Jongphil Kim, Jun Min Zhou, Fatima Tariq, Natalie Burgess, and Hanna Kelly Sanoff. “Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.” In Journal of Clinical Oncology, 36:4082–4082. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.4082.

Full Text

Das, Rahul K., Leon Furchtgott, Jeffrey A. Meyerhardt, Andrew B. Nixon, Federico Innocenti, Daniel Cunha, Kelly Rich, et al. “Causal modeling of CALGB 80405 (Alliance) to identify network drivers of metastatic colorectal cancer (CRC).” In Journal of Clinical Oncology, 36:3570–3570. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.3570.

Full Text

Seligmann, Jenny F., Ace J. Hatch, Susan D. Richman, Faye Elliott, Bart Jacobs, Sarah Brown, Herbert Hurwitz, et al. “Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer.” Jama Oncol 4, no. 4 (April 1, 2018): 564–68. https://doi.org/10.1001/jamaoncol.2017.3168.

PMID
29075780
Full Text

Pages